A comparative trial over three days
The researchers studied nine middle-aged people without diabetes. On three separate days, each participant received either a control without quinine, 300 mg or 600 mg of quinine hydrochloride. The order of the interventions was randomized, and the trial was double-blind.
Quinine was administered directly into the stomach, 60 minutes before a standardized meal consisting of a beef burger and a glucose drink. This route of administration means the results cannot be directly extrapolated to drinking a bitter beverage or consuming a commercial product.
Blood glucose, insulin and glucagon were monitored before the meal and for the following 120 minutes. Gastric emptying was measured by scintigraphy, a method used to track the meal as it leaves the stomach.
Lower glucose without slower gastric emptying
Both amounts of quinine reduced blood glucose just before the meal, as well as the overall blood glucose response and the post-meal peak, compared with the control. The abstract describes a dose-dependent effect but does not report the absolute magnitude of these reductions. Their practical significance therefore remains difficult to assess.
With 600 mg, the researchers also observed an increase in insulin before the meal. Higher pre-meal blood insulin levels were associated with a lower subsequent blood glucose response. These observations support a role for insulin in the measured effect, without establishing the entire causal chain on their own.
By contrast, no change in glucagon or gastric emptying was observed. Under these experimental conditions, slower movement of the meal out of the stomach therefore does not appear to explain the reduction in blood glucose.
What this trial cannot establish
The study examines the response to a single meal in a very small number of people without diabetes. It demonstrates neither a lasting improvement in blood glucose control, nor diabetes prevention, nor a benefit for people who already have diabetes.
The abstract provided also does not allow an adequate assessment of tolerability, interactions or the safety of repeated use. These findings are a research lead, not a protocol to replicate.
Limitations to keep in mind
Nine participants without diabetes, acute observation and administration directly into the stomach. Absolute effects, funding and conflicts of interest cannot be verified from the excerpt provided. Only the PubMed abstract was consulted, not the full text.
What we can take away
Quinine reduced the blood glucose response to a meal in this small trial without slowing gastric emptying. The clinical value and safety of repeated use remain to be established.
Sources and provenance
- Intragastric administration of the bitter tastant, quinine, reduces postprandial plasma glucose without affecting gastric emptying in health.
Source date: 2026-11-18.
Journal Article, Randomized Controlled Trial · Résumé PubMed uniquement, texte intégral non consulté


